0	10	calcitriol	placebo	osteocalcin and β - CrossLaps .	At 1 year follow-up, no significant differences were observed between calcitriol and placebo groups for osteocalcin and β-CrossLaps.
1	23	calcitriol	placebo	osteocalcin and β - CrossLaps .	At 1 year follow-up, no significant differences were observed between calcitriol and placebo groups for osteocalcin and β-CrossLaps.
2	79	calcitriol	placebo	OC and β - CrossLaps levels	At 1 year follow-up, OC and β-CrossLaps levels did not change significantly compared to diagnosis nor in the placebo not in the calcitriol-treated group.
3	80	calcitriol	placebo	β - CrossLaps	No significant differences were observed between calcitriol and placebo groups for OC (37.2±11.8 ng/ml vs 25.8±7.4 ng/ml; P = 0.39) and β-CrossLaps (0.33±0.07 ng/ml vs 0.50±0.12 ng/ml; P = 0.29) (table 2).
4	80	calcitriol	placebo	OC	No significant differences were observed between calcitriol and placebo groups for OC (37.2±11.8 ng/ml vs 25.8±7.4 ng/ml; P = 0.39) and β-CrossLaps (0.33±0.07 ng/ml vs 0.50±0.12 ng/ml; P = 0.29) (table 2).
